Talaris Therapeutics, Inc.

The momentum for this stock is not very good. Talaris Therapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Talaris Therapeutics, Inc..

News

14,773 Shares in Talaris Therapeutics, Inc. (NASDAQ:TALS) Bought by Bailard Inc.

Zolmax Bailard Inc. purchased a new position in shares of Talaris Therapeutics, Inc. (NASDAQ:TALS Free Report) during the 1st quarter, according to the company in its most recent disclosure with...\n more…

Talaris Therapeutics: Cashing Out Ahead Of Tourmaline Merger

SeekingAlpha Talaris Therapeutics has agreed to merge with a late-stage biopharma Tourmaline Bio. Click here to see why TALS stock is a Sell.\n more…

TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS

Business Wire Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed merger of Talaris Therapeutics, Inc. (NasdaqGM: TALS) with Tourmaline Bio, Inc. pursuant to which Talaris shareholders will end up owning...\n more…

Talaris Therapeutics announces merger after layoffs

Bizjournals.com - Health Care News The company anticipates making a cash dividend of up to about $64.8 million to its stockholders prior to the closing of the deal.\n more…

Why Talaris Therapeutics Stock Is Shooting Higher Today

Benzinga Talaris Therapeutics Inc (NASDAQ: TALS) and Tourmaline Bio, Inc have entered into a definitive agreement for a merger in an all-stock transaction, and the combined company will operate under the name Tourmaline Bio Inc trade on the Nasdaq\n more…

Talaris Soars on All Stock Deal with Tourmaline Bio

TipRanks Financial Blog Shares of cell therapy company Talaris Therapeutics (NASDAQ:TALS) are up nearly 26% at the time of writing today after it agreed to merge with biotechnology company...\n more…